Application of bacillus subtilis ZMF7-2
By using Bacillus subtilis ZMF7-2 to prepare fermented feed, which secretes metabolites such as short-chain fatty acids, the problem of uncertain safety and efficacy of probiotics was solved. It significantly enhanced intestinal barrier function and antioxidant capacity, and alleviated intestinal inflammation and tight junction damage.
Patent Information
- Application Number
- CN202411022466.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing probiotics have safety concerns and lack in vivo validation in relieving intestinal inflammation and enhancing intestinal barrier function. In particular, probiotics of unclear origin may have altered gene sequences in the gut due to antibiotic stimulation, leading to uncertain efficacy.
Using Bacillus subtilis ZMF7-2, fermented feed was prepared to secrete metabolites such as short-chain fatty acids, which significantly upregulated the expression levels of ZO1, ZO2, and Occludin genes and proteins in IPEC-J2 cells, enhanced intestinal barrier function, and significantly improved SOD activity and enhanced intestinal antioxidant function through the application of fermented feed.
Bacillus subtilis ZMF7-2 significantly improves intestinal barrier function, prevents tight junction damage, effectively alleviates intestinal inflammation, enhances intestinal antioxidant capacity, and protects intestinal barrier homeostasis.
Smart Images

Figure CN118976049A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, and in particular to an application of Bacillus subtilis ZMF7-2. Background Art
[0002] The intestine is an important digestive and immune organ for humans and animals. Clinically, intestinal diseases can be divided into two categories: functional diseases and organic diseases. Functional intestinal diseases mainly include irritable bowel syndrome and functional dyspepsia; organic diseases include inflammatory bowel disease and intestinal tumors. Inflammatory bowel disease mainly includes Crohn's disease and ulcerative colitis. Intestinal-related diseases are accompanied by inflammation and damage to the intestinal barrier. In animal production, intestinal health directly determines the feed utilization, growth rate and breeding efficiency of animals. For example, early weaning of piglets can cause diarrhea in piglets, and this process is also closely related to intestinal inflammation and intestinal barrier damage. Therefore, intestinal health problems not only affect human health and living standards, but also affect animal production and development.
[0003] Currently, probiotics have been widely studied and applied in human food and animal production. Studies have found that Pediococcus acidilactici has the effect of relieving ulcerative colitis; Lactobacillus reuteri can efficiently adhere to the intestinal epithelial cells Caco-2 and promote the development of small intestinal villi. In animal production, Akkermansia muciniphila (A. muciniphila) can improve the intestinal health of laying hens; Bifidobacterium complex probiotic preparations can improve the growth performance of suckling piglets, reduce the diarrhea rate and mortality during lactation, and can be used to treat piglet diarrhea.
[0004] However, on the one hand, the sources of some probiotics are unclear, and there are potential safety risks; on the other hand, some probiotics come from the intestines and feces of humans and animals, and the probiotics that reside in the intestines may be stimulated by the host taking antibiotics and other drugs for a long time, and their gene sequences may have changed, and their safety may also be a potential safety hazard. In addition, although some probiotics have shown the effect of protecting intestinal health in in vitro cell tests, there is a lack of the most convincing in vivo tests to prove it. Therefore, screening food-borne probiotics that can relieve intestinal inflammation and barrier damage has great social needs and broad application prospects. Summary of the invention
[0005] The purpose of the present invention is to provide an application of Bacillus subtilis ZMF7-2, which can significantly upregulate the expression levels of ZO1, ZO2, Occludin genes and proteins in IPEC-J2 cells, relieve intestinal inflammation, and enhance intestinal barrier function.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides an application of Bacillus subtilis ZMF7-2 in preparing a product for alleviating intestinal inflammation and enhancing intestinal barrier function. The preservation number of the Bacillus subtilis is CCTCC NO: M 20232186.
[0008] Preferably, the Bacillus subtilis ZMF7-2 can be used to prepare food, medicine or health products that relieve intestinal inflammation and enhance intestinal barrier function.
[0009] Preferably, the Bacillus subtilis ZMF7-2 can be used to prepare fermented feed for enhancing the intestinal barrier function.
[0010] Preferably, the method for preparing the fermented feed for enhancing intestinal barrier function is:
[0011] (1) preparing a fermentation raw material by mixing 35-45 parts of corn, 35-45 parts of soybean meal, and 15-25 parts of bran;
[0012] (2) taking 15-20% of the total mass of the fermentation raw material, the mass is recorded as M, taking 2-3% of the mass fraction of the raw material from the fermentation raw material of step (1), adding 1%-1.6%M of brown sugar and 0.1%-1%M of salt, and adding water to make the mass M, to obtain an activated medium; adding 0.1-0.2% of Bacillus subtilis ZMF7-2 powder to the activated medium, culturing for 4-5 hours, stirring once every 15 minutes, and obtaining a microbial composite fermentation seed liquid;
[0013] (3) 30-35% of the microbial composite fermentation seed liquid and 65-70% of the fermentation raw materials are mixed and anaerobically fermented for 2-4 days to obtain a fermented feed that enhances the intestinal barrier function.
[0014] Preferably, the fermentation raw material consists of 40 parts of corn, 40 parts of soybean meal and 20 parts of bran.
[0015] Preferably, the amount of Bacillus subtilis ZMF7-2 powder added to the activation medium is 0.1%.
[0016] The beneficial effects of the present invention compared with the prior art are:
[0017] (1) The Bacillus subtilis ZMF7-2 provided by the present invention can secrete metabolites such as short-chain fatty acids that are beneficial to the intestinal barrier function. After treating intestinal cells with the metabolites of Bacillus subtilis ZMF7-2, the expression levels of ZO1, ZO2, and Occludin genes and proteins in IPEC-J2 cells can be significantly upregulated, thereby enhancing the intestinal barrier function; it can also prevent intestinal tight junction damage and effectively alleviate intestinal inflammation.
[0018] (2) Using the Bacillus subtilis ZMF7-2 provided by the present invention to prepare fermented feed can significantly increase the activity of SOD, enhance the antioxidant function of the intestine, and thus protect the homeostasis of the intestinal barrier. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0020] Figure 1 Analysis of the content of short-chain fatty acids in the culture medium of Bacillus subtilis ZMF7-2 in Example 1;
[0021] Figure 2 The effect of the supernatant of the culture medium of Bacillus subtilis ZMF7-2 on the expression of tight junction proteins in IPEC-J2 cells in Example 2, wherein A is the gene expression level of ZO1, ZO2, and Occludin, and B is the protein expression level of Occludin and ZO1;
[0022] Figure 3 The expression levels of Occludin and ZO1 proteins in IPEC-J2 cells after treatment with the supernatant of Bacillus subtilis ZMF7-2 culture medium in Example 3;
[0023] Figure 4 The expression levels of genes and proteins related to the intestinal tissues of mice after oral administration of Bacillus subtilis ZMF7-2 in Example 4, wherein A is the TNFα gene expression level in the jejunum tissue; B is the IL-6 gene expression level in the jejunum tissue; C is the ZO1 and Occludin protein expression levels in the jejunum tissue; D is the TNFα gene expression level in the colon tissue; E is the IL-6 gene expression level in the colon tissue; and F is the ZO1 and Occludin protein expression levels in the colon tissue;
[0024] Figure 5 The protein expression levels of intestinal tissues of fattening pigs after feeding the fermented feed that enhances the intestinal barrier function in Example 5, wherein A is the protein expression level of intestinal tight junction proteins Claudin2, Claudin3 and ZO1; B is the protein expression level of Claudin1 and Occludin; C is SOD activity, D is CAT activity, and E is MDA content. DETAILED DESCRIPTION
[0025] The embodiments of the present invention are described in detail below, and the embodiments are intended to explain the present invention and should not be construed as limiting the present invention. If specific techniques or conditions are not specified in the embodiments, they are carried out according to the techniques or conditions described in the literature in this area or according to the product specifications. If the manufacturers of reagents or instruments are not specified, they are all conventional products that can be obtained commercially.
[0026] The present invention provides an application of Bacillus subtilis ZMF7-2 in the preparation of a product for relieving intestinal inflammation and enhancing intestinal barrier function. The Latin name of the Bacillus subtilis ZMF7-2 used is Bacillus subtilis, and the strain is preserved in the China Type Culture Collection in Wuhan. The preservation date is November 17, 2023, and the preservation number is: CCTCCNO: M20232186.
[0027] Example 1
[0028] Example 1 of the present invention detected the metabolites of Bacillus subtilis ZMF7-2, and the specific method is as follows:
[0029] Bacillus subtilis ZMF7-2 was inoculated into LB medium and cultured until OD 600nm When the pH value was ≈1.0, the bacterial solution was collected, centrifuged at 5000 rpm for 5 min, the supernatant was aspirated, and sterilized by filtering with a 0.22 μm filter. The filtered culture supernatant was stored at -80°C. Metabolite detection of the culture supernatant was performed at Myvi Metabolism Company. The control group was LB culture medium. The results are shown in Figure 1 .
[0030] The culture medium used was Luria-Bertani (LB) medium, and the formula was: Tryptone 10 g / L, yeast extract 5 g / L, and sodium chloride (NaCl) 10 g / L.
[0031] Figure 1 The results showed that the content of short-chain fatty acids such as 4-guanidinobutyric acid, glutaric acid, valeric acid, and isobutyric acid in the supernatant of Bacillus subtilis culture medium was significantly increased, indicating that Bacillus subtilis ZMF7-2 can secrete short-chain fatty acids and other metabolites that are beneficial to intestinal barrier function.
[0032] Example 2
[0033] Example 2 of the present invention detected the effect of Bacillus subtilis ZMF7-2 on the expression of related proteins in porcine small intestinal epithelial cells IPEC-J2, and the specific method was as follows:
[0034] (1) Preparation of culture medium supernatant:
[0035] Take 1 mL of Example 1 and culture until OD 600nm ≈1.0 of bacterial solution was added to a conical flask containing 100 mL of LB medium and cultured in a 37°C constant temperature incubator for 12 hours at 180 rpm. The bacterial solution was then centrifuged (5000 rpm, 5 min) and the supernatant was collected. The supernatant was sterilized by filtering with a 0.22 μm filter membrane and then used to treat cells.
[0036] (2) Effects of different concentrations of culture supernatant on the expression of tight junction proteins in IPEC-J2 cells:
[0037] When IPEC-J2 cells grew to a confluence rate of about 90%, they were digested with trypsin and then collected. They were centrifuged at 1000 rpm for 4 min, the supernatant was discarded, the cells were resuspended in culture medium, pipetted and mixed, and 2 × 10 5 Cells / well were inoculated into 12-well plates. When the cells grew to a confluence rate of about 80%, the medium was replaced with complete medium containing 0%, 1%, 5%, and 10% of Bacillus subtilis culture medium supernatant, respectively. Samples were collected after culturing for 24 hours.
[0038] Growth medium: high glucose medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% double antibiotics (penicillin and streptomycin).
[0039] (3) Real-time fluorescence quantitative PCR (RT-qPCR) detection of tight junction protein mRNA expression
[0040] The 12-well cell culture plate that reached the sampling time was rinsed with PBS three times, and then 500 μL Total RNA Extraction Reagent (Yisheng Biotechnology, 19202ES60) was added to each well. The total RNA of IPEC-J2 cells was extracted using the total RNA extraction kit TRIzol reagent (Yisheng Biotechnology), and then reversed into cDNA using the reverse transcription cDNA kit ReverAid First Strand cDNA Synthesis Kit (Thermo Fisher) for RT-qPCR detection. The results are shown in Figure 2 The porcine primer sequences used are as follows:
[0041] ZO1 Forward(SEQ ID NO.1)GCCATCCACTCCTGCCTAT;
[0042] ZO1 Reverse(SEQ ID NO.2)CGGGACCTGCTCATAACTTC;
[0043] ZO2 Forward(SEQ ID NO.3)ATTCGGACCCATAGCAGACATAG;
[0044] ZO2 Reverse(SEQ ID NO4.)GCGTTCTCTTGGTTCTGTTTTAGC;
[0045] Occludin Forward(SEQ ID NO.5)CTACTCGTCCAACGGGAAAG;
[0046] Occludin Reverse(SEQ ID NO.6)ACGCCTCCAAGTTACCACTG;
[0047] Claudin1 Forward (SEQ ID NO.7)AAGGACAAAACCGTGTGGGA;
[0048] Claudin1 Reverse(SEQ ID NO.8)CTCTCCCCACATTCGAGATGATT;
[0049] GAPDH Forward(SEQ ID NO.9)CCCCTTCATTGACCTCCACT;
[0050] GAPDH Reverse (SEQ ID NO. 10)TGGAAGATGGTGATGGCCTT.
[0051] Figure 2 Figure A shows that compared with the control group, 5% culture supernatant can significantly increase the expression level of Occludin in IPEC-J2 cells, and adding 10% culture supernatant can significantly upregulate the expression levels of ZO1, ZO2, and Occludin genes in IPEC-J2 cells.
[0052] (4) Western Blot to detect the expression of tight junction proteins:
[0053] The 12-well cell culture plate that reached the sampling time was rinsed with PBS three times, and then 130 μL of Western cell lysis buffer (Biyuntian, P0013) was added to each well, lysed on ice for 10 minutes, and centrifuged for 10 minutes (12000rpm, 4°C). Take 100 μL of supernatant, add 25 μL of 5X loading buffer (Fude Biotechnology, FD002), incubate at 100°C for 10 minutes, and then use it for Western Blot experiments. The results are shown in Figure 2 .
[0054] Figure 2 Figure B shows that compared with the control group (0% supernatant addition group), the addition of 5% culture supernatant can significantly increase the expression of Occludin protein in IPEC-J2 cells, and the addition of 10% culture supernatant can significantly increase the expression levels of Occludin and ZO1 proteins in IPEC-J2 cells. The above results show that Bacillus subtilis ZMF7-2 can increase the expression of tight junction proteins in IPEC-J2 and enhance the intestinal barrier function.
[0055] Example 3
[0056] Example 3 of the present invention uses a 2×2 double factor experimental design to detect the protective effect of the culture supernatant of Bacillus subtilis ZMF7-2 on lipopolysaccharide (LPS)-induced intestinal barrier damage. The specific method is as follows:
[0057] When IPEC-J2 cells grew to a confluence rate of about 90%, they were digested with trypsin and then collected. They were centrifuged at 1000 rpm for 4 min, the supernatant was discarded, the cells were resuspended in culture medium, pipetted and mixed, and 2 × 10 5 Cells / well were seeded into 12-well plates.
[0058] Divided into 4 groups: ① Growth medium without LPS, ② Growth medium + 10% culture medium supernatant, ③ Growth medium with 10μg / mL LPS, ④ Growth medium + 10% culture medium supernatant with 10μg / mL LPS. When the cells grow to a confluence rate of about 80%, the medium is replaced with growth medium or growth medium + 10% culture medium supernatant. After 24 hours of culture, the medium is replaced with growth medium or growth medium containing 10μg / mL LPS. After 24 hours of culture, samples are collected for Western Blot detection. The results are shown in Figure 3 .
[0059] Figure 3 The results showed that compared with the group with 0% culture supernatant addition, the addition of 10% culture supernatant significantly increased the expression levels of Occludin and ZO1 proteins in IPEC-J2 cells; compared with the group with 0% culture supernatant addition, LPS treatment (0% + LPS) reduced the expression levels of Occludin and ZO1 proteins in IPEC-J2 cells, while treatment with 10% culture supernatant for 24 hours before LPS treatment significantly increased the expression levels of Occludin and ZO1 proteins, indicating that metabolites derived from Bacillus subtilis ZMF7-2 can prevent intestinal tight junction damage caused by LPS stimulation and maintain intestinal barrier function.
[0060] Example 4
[0061] Example 4 of the present invention detected the therapeutic effect of Bacillus subtilis ZMF7-2 on intestinal inflammation and barrier damage in mice, and the specific method is as follows:
[0062] (1) Twenty healthy C57BL / 6 male mice aged 8 weeks were randomly divided into 4 groups: blank group (PBS group), Bacillus subtilis gavage group (BS), LPS group, and LPS+BS group. The mice were continuously gavaged with PBS or Bacillus subtilis (1×10 9 CFU) for 13 days. On the morning of the 14th day, LPS (1 mg / kg body weight) was injected intraperitoneally in the LPS group and the LPS+BS group, and the same dose of saline was injected intraperitoneally in the PBS group and the BS group. Samples were collected after 6 hours of dissection and frozen.
[0063] (2) RT-qPCR detection of mRNA expression of genes related to intestinal inflammation
[0064] Take about 0.1 g of frozen tissue into a 1.5 mL centrifuge tube, add 0.5 mL TRIzol reagent and 3 homogenizing steel beads; homogenize in a homogenizer for 5 min (-5°C, 60 Hz); then place on ice for lysis for 30 min.
[0065] Total RNA extraction, RT-qPCR, protein extraction and Western Blot experiments were performed using the method of Example 2. The primer sequences of the mice used are as follows:
[0066] b-actin Forward (SEQ ID NO.11)GGCTGTATTCCCCTCCATCG;
[0067] b-actin Reverse (SEQ ID NO.12)CCAGTTGGTAACAATGCCATGT;
[0068] TNF-a Forward (SEQ ID NO. 13)GGTGCCTATGTCTCAGCCTCTT;
[0069] TNF-a Reverse (SEQ ID NO. 14) GCCATAGAACTGATGAGAGGGAG;
[0070] IL-6Forward(SEQ ID NO.15)TACCACTTCACAAGTCGGAGGC;
[0071] IL-6Reverse (SEQ ID NO. 16)CTGCAAGTGCATCATCGTTGTTC.
[0072] Figure 4It was shown that, without LPS stimulation, intragastric administration of Bacillus subtilis ZMF7-2 could significantly reduce the gene expression levels of inflammatory factors TNFα and IL-6 in jejunal tissue ( Figure 4 After LPS stimulation, the gene expression of inflammatory factors TNFα and IL-6 in jejunum tissue was significantly increased ( Figure 4 Compared with the LPS group, BS treatment significantly reduced the gene expression levels of inflammatory factors TNFα and IL-6 in jejunal tissue ( Figure 4 A and B in the middle indicate that Bacillus subtilis ZMF7-2 can effectively alleviate LPS-induced intestinal inflammation. At the protein level, LPS stimulation significantly reduced the expression levels of ZO1 and Occludin proteins in jejunal tissue, while Bacillus subtilis ZMF7-2 can restore the expression levels of ZO1 and Occludin proteins, thereby protecting the intestinal barrier function ( Figure 4 In colon tissue, LPS stimulation caused an increase in the gene expression of inflammatory factors TNFα and IL-6, while Bacillus subtilis ZMF7-2 could significantly reduce the gene expression levels of inflammatory factors TNFα and IL-6 ( Figure 4 D, E); At the protein level, oral administration of Bacillus subtilis ZMF7-2 significantly increased the expression level of Occludin protein, LPS stimulation reduced the expression of ZO1 protein in the colon, and oral administration of Bacillus subtilis ZMF7-2 could restore the expression of ZO1 protein ( Figure 4 Middle F).
[0073] Example 5
[0074] Example 5 of the present invention detected the protective effect of Bacillus subtilis ZMF7-2 on the intestinal barrier function of fattening pigs, and the specific method is as follows:
[0075] (1) Preparation of fermented feed
[0076] The mass parts of the fermentation raw materials are: 40 parts of corn, 40 parts of soybean meal, and 20 parts of bran.
[0077] Take 15% of the total mass of the fermentation raw material, and record the mass as M; take 2% of the raw material by mass from the fermentation raw material, add 1%M of brown sugar and 0.1%M of salt, and add water to make up to the mass of M to obtain an activated medium. Then add 0.1% of Bacillus subtilis powder to the activated medium, stir every 15 minutes, and culture for 4 hours to obtain a microbial composite fermentation seed liquid. Add the microbial composite fermentation seed liquid to the fermentation raw material, add it to about 35% of the fermentation system, and stir it thoroughly. Put the mixed fermentation system into an anaerobic breathing bag and let it stand for fermentation for 3 days before use.
[0078] (2) Experimental design
[0079] 144 fattening pigs of similar weight were randomly divided into three groups, each with 48 pigs. The three groups were fed with basal diet, basal diet + 5% fermented feed, and basal diet + 10% fermented feed. The composition of the basal diet is shown in Table 1. Twelve fattening pigs were raised in each pen, and free drinking water and feeding were guaranteed; they were fed three times a day: 7:30, 13:30, and 17:30. The trial period was 38 days, and serum and intestinal tissue samples were taken on the day of the trial.
[0080] Table 1 Composition and nutritional level of experimental diets (%, air-dry basis). 1
[0081]
[0082] (3) Detection of mRNA and protein expression of intestinal tight junction proteins
[0083] The mRNA and protein expression levels of intestinal tight junction proteins were detected using step (2) of Example 4. The results are shown in Figure 5 . Figure 5 Figure A shows that adding 5% fermented feed to the fattening pig diet significantly increased the expression of colon ZO1 gene, and adding 10% fermented feed significantly increased the expression levels of Claudin2, Claudin3 and ZO1 proteins. Figure 5 The Western Blot results of B showed that the addition of 5% and 10% fermented feed increased the protein expression levels of ZO1 and Occludin, and the 10% group had a better effect.
[0084] (4) Determination of intestinal antioxidant enzyme activity
[0085] All the kits for the detection of antioxidant enzyme activity and malondialdehyde (MDA) in intestinal tissue were purchased from Nanjing Jiancheng Bioengineering Institute. The relevant operations were carried out according to the instructions. The results are shown in Figure 5 Middle C~E.
[0086] Figure 5 Figures C to E show that compared with the basic diet group, adding 10% fermented feed did not affect the activity of catalase (CAT) and MDA content, but significantly increased the activity of superoxide dismutase (SOD), indicating that adding fermented feed can enhance the antioxidant function of the intestine of fattening pigs and thus protect the homeostasis of the intestinal barrier.
[0087] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An application of Bacillus subtilis ZMF7-2 in the preparation of a product for relieving intestinal inflammation and enhancing intestinal barrier function, characterized in that: The deposit number of the Bacillus subtilis is CCTCCNO: M 20232186.
2. The use of Bacillus subtilis ZMF7-2 according to claim 1 in preparing a product for alleviating intestinal inflammation and enhancing intestinal barrier function, characterized in that: The Bacillus subtilis ZMF7-2 can be used to prepare food, medicine or health products that relieve intestinal inflammation and enhance intestinal barrier function.
3. The use of Bacillus subtilis ZMF7-2 according to claim 1 in preparing a product for alleviating intestinal inflammation and enhancing intestinal barrier function, characterized in that: The Bacillus subtilis ZMF7-2 can be used to prepare fermented feed that enhances intestinal barrier function.
4. The use of Bacillus subtilis ZMF7-2 according to claim 2 in preparing a product for relieving intestinal inflammation and enhancing intestinal barrier, characterized in that: The preparation method of the fermented feed for enhancing the intestinal barrier function is as follows: (1) preparing a fermentation raw material by mixing 35-45 parts of corn, 35-45 parts of soybean meal, and 15-25 parts of bran; (2) taking 15-20% of the total mass of the fermentation raw material, the mass is recorded as M, taking 2-3% of the mass fraction of the raw material from the fermentation raw material of step (1), adding 1%-1.6%M of brown sugar and 0.1%-1%M of salt, and adding water to make the mass M, to obtain an activated medium; adding 0.1-0.2% of Bacillus subtilis ZMF7-2 powder to the activated medium, culturing for 4-5 hours, stirring once every 15 minutes, and obtaining a microbial composite fermentation seed liquid; (3) 30-35% of the microbial composite fermentation seed liquid and 65-70% of the fermentation raw materials are mixed and anaerobically fermented for 2-4 days to obtain a fermented feed that enhances the intestinal barrier function.
5. The use of Bacillus subtilis ZMF7-2 according to claim 4 in preparing a product for relieving intestinal inflammation and enhancing intestinal barrier, characterized in that: The fermentation raw material consists of 40 parts of corn, 40 parts of soybean meal and 20 parts of bran.
6. The use of Bacillus subtilis ZMF7-2 according to claim 4 in preparing a product for relieving intestinal inflammation and enhancing intestinal barrier, characterized in that: The amount of Bacillus subtilis ZMF7-2 powder added to the activation culture medium is 0.1%.
Citation Information
Patent Citations
Broad spectrum pathogenic bacterium resisting bacillus subtilis and application thereof
CN106190933A
Fermented feed for improving productivity of sows as well as preparation method and application of fermented feed
CN107683972A
Bacillus subtilis strain with probiotic activity
CN109207390A
Bacillus subtilis having effects of relieving enteritis and promoting development of intestines and application
CN110144310A
Bacillus subtilis ZMF7-2 and application thereof in degradation of various mycotoxins and cholesterol
CN118126868A
